Semin Plast Surg 2009; 23(3): 178-184
DOI: 10.1055/s-0029-1224797
© Thieme Medical Publishers

Keloids: Pathogenesis, Clinical Features, and Management

Chuma J. Chike-Obi1 , Patrick D. Cole1 , Anthony E. Brissett2
  • 1Division of Plastic Surgery, Baylor College of Medicine, Houston, Texas
  • 2Bobby R. Alford Department of Otorhinolaryngology, Baylor College of Medicine, Houston, Texas
Further Information

Publication History

Publication Date:
13 July 2009 (online)

ABSTRACT

Cutaneous wound healing is a complex response to skin injury. Deregulation of this process can lead to excessive scar formation, as seen in keloids. Keloids are common skin lesions that are difficult to treat and are associated with high recurrence rates despite the large number of available treatment options. With increased knowledge of the disease process and further scientific advancements, future approaches will hopefully improve keloid treatment. In this article, we review the epidemiology, genetic basis, etiology, clinical features, pathogenesis, and management of keloids.

REFERENCES

  • 1 Bayat A, Bock O, Mrowietz U, Ollier W E, Ferguson M W. Genetic susceptibility to keloid disease and hypertrophic scarring: transforming growth factor beta1 common polymorphisms and plasma levels.  Plast Reconstr Surg. 2003;  111 535-543 discussion 544-546
  • 2 Brissett A E, Sherris D A. Scar contractures, hypertrophic scars, and keloids.  Facial Plast Surg. 2001;  17 263-272
  • 3 Marneros A G, Krieg T. Keloids—clinical diagnosis, pathogenesis, and treatment options.  J Dtsch Dermatol Ges. 2004;  2 905-913
  • 4 Messadi D V, Le A, Berg S, Huang G, Zhuang W, Bertolami C N. Effect of TGF-beta 1 on PDGF receptors expression in human scar fibroblasts.  Front Biosci. 1998;  3 a16-a22
  • 5 Sayah D N, Soo C, Shaw W W et al.. Downregulation of apoptosis-related genes in keloid tissues.  J Surg Res. 1999;  87 209-216
  • 6 De Felice B, Ciarmiello L F, Mondola P et al.. Differential p63 and p53 expression in human keloid fibroblasts and hypertrophic scar fibroblasts.  DNA Cell Biol. 2007;  26 541-547
  • 7 Lu F, Gao J, Ogawa R, Hyakusoku H. Variations in gap junctional intercellular communication and connexin expression in fibroblasts derived from keloid and hypertrophic scars.  Plast Reconstr Surg. 2007;  119 844-851
  • 8 Chevray P M, Manson P N. Keloid scars are formed by polyclonal fibroblasts.  Ann Plast Surg. 2004;  52 605-608
  • 9 Berman B, Flores F. The treatment of hypertrophic scars and keloids.  Eur J Dermatol. 1998;  8 591-595
  • 10 Ichioka S, Ando T, Shibata M, Sekiya N, Nakatsuka T. Oxygen consumption of keloids and hypertrophic scars.  Ann Plast Surg. 2008;  60 194-197
  • 11 Sasaki A, Mueller R V, Xi G, Sipe R, Buck D, Hollinger J. Mast cells: an unexpected finding in the modulation of cutaneous wound repair by charged beads.  Plast Reconstr Surg. 2003;  111 1446-1453
  • 12 Sharquie K E, Al-Dhalimi M A. Keloid in Iraqi patients: a clinicohistopathologic study.  Dermatol Surg. 2003;  29 847-851
  • 13 Lee S S, Yosipovitch G, Chan Y H, Goh C L. Pruritus, pain, and small nerve fiber function in keloids: a controlled study.  J Am Acad Dermatol. 2004;  51 1002-1006
  • 14 Aköz T, Gideroğlu K, Akan M. Combination of different techniques for the treatment of earlobe keloids.  Aesthetic Plast Surg. 2002;  26 184-188
  • 15 Kelly A P. Medical and surgical therapies for keloids.  Dermatol Ther. 2004;  17 212-218
  • 16 Ramakrishnan K M, Thomas K P, Sundararajan C R. Study of 1,000 patients with keloids in South India.  Plast Reconstr Surg. 1974;  53 276-280
  • 17 Marneros A G, Norris J E, Olsen B R, Reichenberger E. Clinical genetics of familial keloids.  Arch Dermatol. 2001;  137 1429-1434
  • 18 Marneros A G, Norris J E, Watanabe S, Reichenberger E, Olsen B R. Genome scans provide evidence for keloid susceptibility loci on chromosomes 2q23 and 7p11.  J Invest Dermatol. 2004;  122 1126-1132
  • 19 Bayat A, Arscott G, Ollier W E, Ferguson M W, Mc Grouther D A. Description of site-specific morphology of keloid phenotypes in an Afrocaribbean population.  Br J Plast Surg. 2004;  57 122-133
  • 20 Poochareon V N, Berman B. New therapies for the management of keloids.  J Craniofac Surg. 2003;  14 654-657
  • 21 Chen M A, Davidson T M. Scar management: prevention and treatment strategies.  Curr Opin Otolaryngol Head Neck Surg. 2005;  13 242-247
  • 22 Mustoe T A, Cooter R D, Gold M H et al.. International clinical recommendations on scar management.  Plast Reconstr Surg. 2002;  110 560-571
  • 23 Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids.  J Am Acad Dermatol. 2002;  47(4, Suppl) S209-S211
  • 24 Niessen F B, Spauwen P H, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: a review.  Plast Reconstr Surg. 1999;  104 1435-1458
  • 25 Alster T S, Tanzi E L. Hypertrophic scars and keloids: etiology and management.  Am J Clin Dermatol. 2003;  4 235-243
  • 26 Rudy S J. Imiquimod (Aldara): modifying the immune response.  Dermatol Nurs. 2002;  14 268-270
  • 27 Weeks C E, Gibson S J. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro.  J Interferon Res. 1994;  14 81-85
  • 28 Jacob S E, Berman B, Nassiri M, Vincek V. Topical application of imiquimod 5% cream to keloids alters expression genes associated with apoptosis.  Br J Dermatol. 2003;  149(Suppl 66) 62-65
  • 29 Malhotra A K, Gupta S, Khaitan B K, Sharma V K. Imiquimod 5% cream for the prevention of recurrence after excision of presternal keloids.  Dermatology. 2007;  215 63-65
  • 30 Bilu D, Sauder D N. Imiquimod: modes of action.  Br J Dermatol. 2003;  (149 Suppl 66) 5-8
  • 31 Berman B, Duncan M R. Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro.  J Am Acad Dermatol. 1989;  21(4 Pt 1) 694-702
  • 32 Duncan M R, Berman B. Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons.  J Clin Invest. 1987;  79 1318-1324
  • 33 Davison S P, Mess S, Kauffman L C, Al-Attar A. Ineffective treatment of keloids with interferon alpha-2b.  Plast Reconstr Surg. 2006;  117 247-252
  • 34 al-Khawajah M M. Failure of interferon-alpha 2b in the treatment of mature keloids.  Int J Dermatol. 1996;  35 515-517
  • 35 Wong T W, Chiu H C, Yip K M. Intralesional interferon alpha-2b has no effect in the treatment of keloids.  Br J Dermatol. 1994;  130 683-685
  • 36 Wendling J, Marchand A, Mauviel A, Verrecchia F. 5-Fluorouracil blocks transforming growth factor-beta-induced alpha 2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun NH2-terminal kinase/activator protein-1 activation.  Mol Pharmacol. 2003;  64 707-713
  • 37 Nanda S, Reddy B S. Intralesional 5-fluorouracil as a treatment modality of keloids.  Dermatol Surg. 2004;  30 54-56, discussion 56–57
  • 38 Gupta S, Kalra A. Efficacy and safety of intralesional 5-fluorouracil in the treatment of keloids.  Dermatology. 2002;  204 130-132
  • 39 Uppal R S, Khan U, Kakar S, Talas G, Chapman P, McGrouther A D. The effects of a single dose of 5-fluorouracil on keloid scars: a clinical trial of timed wound irrigation after extralesional excision.  Plast Reconstr Surg. 2001;  108 1218-1224
  • 40 Lee D A. Antifibrosis agents and glaucoma surgery.  Invest Ophthalmol Vis Sci. 1994;  35 3789-3791
  • 41 Sanders K W, Gage-White L, Stucker F J. Topical mitomycin C in the prevention of keloid scar recurrence.  Arch Facial Plast Surg. 2005;  7 172-175
  • 42 Sewall G K, Robertson K M, Connor N P, Heisey D M, Hartig G K. Effect of topical mitomycin on skin wound contraction.  Arch Facial Plast Surg. 2003;  5 59-62
  • 43 Prutkin L. Wound healing and vitamin A acid.  Acta Derm Venereol. 1972;  52 489-492
  • 44 Christophers E. Growth stimulation of cultured postembryonic epidermal cells by vitamin A acid.  J Invest Dermatol. 1974;  63 450-455
  • 45 Janssen de Limpens A M. The local treatment of hypertrophic scars and keloids with topical retinoic acid.  Br J Dermatol. 1980;  103 319-323
  • 46 Daly T J, Weston W L. Retinoid effects on fibroblast proliferation and collagen synthesis in vitro and on fibrotic disease in vivo.  J Am Acad Dermatol. 1986;  15(4 Pt 2) 900-902
  • 47 Al-Attar A, Mess S, Thomassen J M, Kauffman C L, Davison S P. Keloid pathogenesis and treatment.  Plast Reconstr Surg. 2006;  117 286-300
  • 48 Ogawa R, Miyashita T, Hyakusoku H, Akaishi S, Kuribayashi S, Tateno A. Postoperative radiation protocol for keloids and hypertrophic scars: statistical analysis of 370 sites followed for over 18 months.  Ann Plast Surg. 2007;  59 688-691
  • 49 Ogawa R, Mitsuhashi K, Hyakusoku H, Miyashita T. Postoperative electron-beam irradiation therapy for keloids and hypertrophic scars: retrospective study of 147 cases followed for more than 18 months.  Plast Reconstr Surg. 2003;  111 547-553, discussion 554–555
  • 50 Nouri K, Vidulich K, Rivas M P. Lasers for scars: a review.  J Cosmet Dermatol. 2006;  5 14-22
  • 51 Apfelberg D B, Maser M R, Lash H, White D, Weston J. Preliminary results of argon and carbon dioxide laser treatment of keloid scars.  Lasers Surg Med. 1984;  4 283-290
  • 52 Apfelberg D B, Maser M R, White D N, Lash H. Failure of carbon dioxide laser excision of keloids.  Lasers Surg Med. 1989;  9 382-388
  • 53 Norris J E. The effect of carbon dioxide laser surgery on the recurrence of keloids.  Plast Reconstr Surg. 1991;  87 44-49, discussion 50–53
  • 54 Atiyeh B S. Nonsurgical management of hypertrophic scars: evidence-based therapies, standard practices, and emerging methods.  Aesthetic Plast Surg. 2007;  31 468-492 discussion 493-494
  • 55 Rusciani L, Paradisi A, Alfano C, Chiummariello S, Rusciani A. Cryotherapy in the treatment of keloids.  J Drugs Dermatol. 2006;  5 591-595
  • 56 Har-Shai Y, Amar M, Sabo E. Intralesional cryotherapy for enhancing the involution of hypertrophic scars and keloids.  Plast Reconstr Surg. 2003;  111 1841-1852
  • 57 Borgognoni L. Biological effects of silicone gel sheeting.  Wound Repair Regen. 2002;  10 118-121
  • 58 de Oliveira G V, Nunes T A, Magna L A et al.. Silicone versus nonsilicone gel dressings: a controlled trial.  Dermatol Surg. 2001;  27 721-726
  • 59 Chang C W, Ries W R. Nonoperative techniques for scar management and revision.  Facial Plast Surg. 2001;  17 283-288
  • 60 Chernoff W G, Cramer H, Su-Huang S. The efficacy of topical silicone gel elastomers in the treatment of hypertrophic scars, keloid scars, and post-laser exfoliation erythema.  Aesthetic Plast Surg. 2007;  31 495-500
  • 61 Mustoe T A. Evolution of silicone therapy and mechanism of action in scar management.  Aesthetic Plast Surg. 2008;  32 82-92
  • 62 Sawada Y, Sone K. Treatment of scars and keloids with a cream containing silicone oil.  Br J Plast Surg. 1990;  43 683-688

Chuma J Chike-ObiM.D. 

Division of Plastic Surgery, Baylor College of Medicine

6701 Fannin, CC610.00, Houston, TX 77030-2399

Email: cjchikeo@bcm.edu

    >